162 related articles for article (PubMed ID: 29589107)
1. Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
Desantis V; Frassanito MA; Tamma R; Saltarella I; Di Marzo L; Lamanuzzi A; Solimando AG; Ruggieri S; Annese T; Nico B; Vacca A; Ribatti D
Ann Hematol; 2018 Jul; 97(7):1251-1258. PubMed ID: 29589107
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
[TBL] [Abstract][Full Text] [Related]
3. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
5. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
[TBL] [Abstract][Full Text] [Related]
7. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.
Ribatti D; Presta M; Vacca A; Ria R; Giuliani R; Dell'Era P; Nico B; Roncali L; Dammacco F
Blood; 1999 Apr; 93(8):2627-36. PubMed ID: 10194442
[TBL] [Abstract][Full Text] [Related]
8. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
[TBL] [Abstract][Full Text] [Related]
9. In vivo angiogenic activity of erythropoietin.
Ribatti D
Methods Mol Biol; 2013; 982():227-35. PubMed ID: 23456873
[TBL] [Abstract][Full Text] [Related]
10. Effects of the fibroblast activation protein on the invasion and migration of gastric cancer.
Wang RF; Zhang LH; Shan LH; Sun WG; Chai CC; Wu HM; Ibla JC; Wang LF; Liu JR
Exp Mol Pathol; 2013 Dec; 95(3):350-56. PubMed ID: 24422232
[TBL] [Abstract][Full Text] [Related]
11. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.
Zi FM; He JS; Li Y; Wu C; Wu WJ; Yang Y; Wang LJ; He DH; Yang L; Zhao Y; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
Cancer Biol Ther; 2014 Oct; 15(10):1413-22. PubMed ID: 25046247
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic activity of multiple myeloma endothelial cells in vivo in the chick embryo chorioallantoic membrane assay is associated to a down-regulation in the expression of endogenous endostatin.
Mangieri D; Nico B; Benagiano V; De Giorgis M; Vacca A; Ribatti D
J Cell Mol Med; 2008 Jun; 12(3):1023-8. PubMed ID: 18494942
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.
Dienus K; Bayat A; Gilmore BF; Seifert O
Arch Dermatol Res; 2010 Dec; 302(10):725-31. PubMed ID: 20872224
[TBL] [Abstract][Full Text] [Related]
17. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
18. Polyphyllin I inhibits gastric cancer cell proliferation by downregulating the expression of fibroblast activation protein alpha (FAP) and hepatocyte growth factor (HGF) in cancer-associated fibroblasts.
Dong R; Guo J; Zhang Z; Zhou Y; Hua Y
Biochem Biophys Res Commun; 2018 Mar; 497(4):1129-1134. PubMed ID: 29499193
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.
Frassanito MA; Rao L; Moschetta M; Ria R; Di Marzo L; De Luisi A; Racanelli V; Catacchio I; Berardi S; Basile A; Menu E; Ruggieri S; Nico B; Ribatti D; Fumarulo R; Dammacco F; Vanderkerken K; Vacca A
Leukemia; 2014 Apr; 28(4):904-16. PubMed ID: 23995611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
